BIgAN II

The role of the gut microbiome in the pathogenesis of lgA nephropathy - the follow up study - BIgAN II

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57522

Enrollment

100

Registered

2025-02-18

Start date

2025-05-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lgA nephropathy, glomerulonephritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Has participated succesfully in the BIgAN study 2021-13006.

Exclusion criteria

Exclusion criteria: No informed consentCurrently on dialysis dialysisHaving received a kidney transplantationCurrently pregnant

Design outcomes

Primary

Measure	Time frame
Does the gastro-intestinal bacterial ecosystem between patients with lgA nephropathy differ from control renal patients and healthy controls? lf so, in what way? Does the gastro-intestinal bacterial ecosystem between patients with lgA nephropathy differ from the first inclusion roughly two years prior and how does this relate to disease progression? Furthermore, how does the proteome of urine/plasma of IgA nephropathy patients differ from the protein compisiton analysed during the first inclusion? How can these proteins predict disease development?	—

Measure

Time frame

Does the gastro-intestinal bacterial ecosystem between patients with lgA nephropathy differ from control renal patients and healthy controls? lf so, in what way? Does the gastro-intestinal bacterial ecosystem between patients with lgA nephropathy differ from the first inclusion roughly two years prior and how does this relate to disease progression? Furthermore, how does the proteome of urine/plasma of IgA nephropathy patients differ from the protein compisiton analysed during the first inclusion? How can these proteins predict disease development?

—

Secondary

Measure	Time frame
How does the proteome of urine/plasma of IgA nephropathy patients differ from the protein compisiton analysed during the first inclusion? How can these proteins predict disease development?	—

Countries

Netherlands

Contacts

Public ContactR Duivenvoorden

Radboud Universitair Medisch Centrum

raphael.duivenvoorden@radboudumc.nl024361461

Outcome results